The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after multi-agent chemotherapy.
Following on from information received from the company this appraisal has now been scheduled back into the work programme.
The appraisal is anticipated to begin during late July 2020 when we will write to you about how you can get involved.